Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Oral Dual Androgen Receptor Ligand-Directed Degrader and Antagonist as Investigational Treatment for Metastatic Castration-Resistant Prostate Cancer

Oral Dual Androgen Receptor Ligand-Directed Degrader and Antagonist as Investigational Treatment for Metastatic Castration-Resistant Prostate Cancer1

​BMS-986365 clinical trial (rechARge trial, CA071-1000) is currently open for enrollment

Find Out More See how BMS-986365 works in mCRPC​

Explore BMS-986365 in mCRPC Trial ​

horizontal line

Clinical Trial Locator Tool Icon

Find a rechARge clinical trial site by location​​

Reference(s)

  1. Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, Srinivas S, Aparicio A, Narayan V, Runcie KD, Emamekhoo H, Reichert ZR, Nguyen MH, Wells AL, Kandimalla R, Liu C, Suryawanshi S, Han J, Wu J, Arora VK, Pourdehnad M, Armstrong AJ. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025 Jan;36(1):76-88. doi: 10.1016/j.annonc.2024.09.005. Epub 2024 Sep 16. PMID: 39293515.

This website is for US physicians to provide general information about ongoing BMS clinical trials and as an exchange of scientific information related to BMS investigational product BMS-986365. BMS-986365 is not currently approved in any market and has not been approved by the FDA.

© 2025 Bristol Myers Squibb Company. All rights reserved.

ONC-US-2500389